ENDONOVO THERAPEUTICS, INC. (ENDV)

Every figure this model derived for ENDV, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-09-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2019-12-31
cash 0 CashAndCashEquivalentsAtCarryingValue 2023-09-30
current assets 35,504 AssetsCurrent 2023-09-30
current liabilities 23,696,070 LiabilitiesCurrent 2023-09-30
equity -22,960,131 StockholdersEquity 2023-09-30
ocf -629,904 NetCashProvidedByUsedInOperatingActivities 2023-09-30
revenue 255,723 RevenueFromContractWithCustomerExcludingAssessedTax 2023-09-30
sbc 45,000 AllocatedShareBasedCompensationExpense 2022-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ENDV on one particular measure came for.

RatioValue
cash operating margin-752.59
current ratio0.0
current ratio reported0.0
dilution pct132.78
fcf margin-246.32
growth cv1.72
operating margin-1023.16
owner earnings margin-263.92
revenue growth1699.85
revenue growth per share673.2
rule of 40676.7
sbc pct revenue17.6

What to be careful about

What this model itself distrusts about ENDV's figures. Written by the derivation as it ran, not added afterwards.